Clopidogrel is a prodrug that is used to treat blood
clots. The irreversible binding of its active metabolite to the P2Y12 class of
ADP receptors on platelets suppresses platelet activation and aggregation.
Platelet aggregation inhibition is dose-dependent and visible 2 hours after
single oral dosages. On the first day, repeated 75 mg doses decrease
ADP-induced platelet aggregation, and inhibition achieves a stable state
between Days 3 and 7.
& Administration of Navix 75 Tablet
Acute Coronary Syndrome:
In patients who need an antiplatelet effect within hours, initiate clopidogrel
with a single 300 mg (4 tablets) oral loading dose and then continue at 75 mg
once daily. Initiating it without a loading dose will delay establishment of an
antiplatelet effect by several days.
Recent MI, Recent Stroke, or Established Peripheral Arterial
Disease: 75 mg once daily orally without a loading dose.
It is given orally with or without food.
of Navix 75 Tablet
- NSAIDs, warfarin, and selective serotonin and
serotonin-norepinephrine reuptake inhibitors (SSRIs, SNRIs): NSAIDs,
warfarin, and selective serotonin and serotonin-norepinephrine reuptake
inhibitors (SSRIs, SNRIs): CYP2C19 inhibitors (omeprazole or esomeprazole):
- Increases the risk of bleeding. Avoid taking omeprazole or
esomeprazole at the same time.
- Repaglinide (substrates for CYP2C8): Clopidogrel should not
be taken with Repaglinide since it raises Repaglinide plasma level.
Clopidogrel should not be used if you have any of
the following conditions: Hypersensitivity to the medicine or any of the
product's components. Peptic ulcer or cerebral hemorrhage are examples of
active pathological bleeding.
Effects of Navix 75 Tablet
Clopidogrel is generally well-tolerated drug.
- Common side effects: Bleeding, Diarrhoea, gastrointestinal
discomfort, hemorrhage, Skin reactions.
- Rare side effects: Acquired hemophilia, anaemia, angioedema,
arthralgia, arthritis, bone marrow disorders.
In pregnant women, there are no sufficient and
well-controlled trials. It should only be used during pregnancy if absolutely
necessary. Clopidogrel is not known to be excreted in human breast milk.
Considering the medicine's value to the mother, a decision should be taken
whether to quit nursing or discontinue the drug.
- Clopidogrel should not be used if you have any of the
following conditions: Because tA is a prodrug, genetic polymorphisms in
CYP2C19 (a poor metabolizer) and medicines that inhibit CYP2C19, such as
Omeprazole and Esomeprazole, hinder metabolism to its active metabolite.
- Clopidogrel's antiplatelet action may be reduced if it is
taken with certain medications or if you have a CYP2C19 poor metabolizer.
- The risk of bleeding may increase since it inhibits platelet
aggregation during the platelet's whole lifetime (7-10 days). Platelet
transfusions given within 4 hours of the loading dosage or 2 hours of the
maintenance dose may be less efficient in restoring hemostasis.
- The risk of bleeding increases if you stop using Clopidogrel.
- TTP (Thrombotic Thrombocytopenic Purpura) is a type of
thrombocytopenic purpura that requires immediate treatment, including
plasmapheresis (plasma exchange).
- Patients on clopidogrel or who have a history of
hypersensitivity to other thienopyridines have suffered rash, angioedema,
or hematologic reactions.
In a dry environment, keep the temperature below
30°C. Protected from the sun's rays. Do not allow yourself to become frozen.
Keep out of children's reach.